OS Therapies (OSTX) News Today $2.25 -0.06 (-2.60%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.24 -0.01 (-0.44%) As of 09/12/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OSTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period D. Boral Capital Reaffirms "Buy" Rating for OS Therapies (NYSE:OSTX)September 4, 2025 | marketbeat.comOS Therapies (NYSE:OSTX) Given Buy Rating at D. Boral CapitalSeptember 3, 2025 | americanbankingnews.comOS Therapies Raises $3.7M for OST-HER2 LaunchSeptember 2, 2025 | tipranks.comD. Boral Capital Reiterates "Buy" Rating for OS Therapies (NYSE:OSTX)August 29, 2025 | marketbeat.comOS Therapies Ends Equity Agreement with Square GateAugust 26, 2025 | tipranks.comOS Therapies Reports Progress in Osteosarcoma TreatmentAugust 25, 2025 | tipranks.comOS Therapies (NYSE:OSTX) Earns "Buy" Rating from D. Boral CapitalAugust 22, 2025 | marketbeat.comOS Therapies Inc Reports Q2 2025 Earnings: Net Loss Per Share at $0.19, Revenue Details UnavailableAugust 19, 2025 | gurufocus.comEarnings Outlook For OS TherapiesAugust 18, 2025 | benzinga.comOS Therapies Updates Quorum Rules for Shareholder MeetingsAugust 15, 2025 | tipranks.comOS Therapies Delays Q2 2025 Financial ReportAugust 15, 2025 | tipranks.comOS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent ...August 9, 2025 | finance.yahoo.comOS Therapies files to sell 3.76M shares of common stock for holdersAugust 6, 2025 | msn.comOS Therapies Inc News (OSTX) - Investing.comJuly 18, 2025 | investing.comOS Therapies Inc. (NYSE-A: OSTX) Makes Important Strides in Rare Cancer TherapyJuly 14, 2025 | theglobeandmail.comOS Therapies Raises $4.2M Through Warrant ExerciseJuly 14, 2025 | tipranks.comOS Therapies Inc.: Promising Cancer Immunotherapy and Strategic Regulatory Advancements Support Buy RatingJuly 11, 2025 | tipranks.comAnalysts Conflicted on These Healthcare Names: OS Therapies Incorporated (OSTX), Korro Bio (KRRO) and Veeva Systems (VEEV)July 3, 2025 | theglobeandmail.comOSTX - OS Therapies Inc Executives - MorningstarJuly 3, 2025 | morningstar.comMOS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic OsteosarcomaJuly 3, 2025 | businesswire.comPositive Buy Rating for OS Therapies Driven by Promising Phase 2b Trial Results and Regulatory ProgressJuly 2, 2025 | tipranks.comOS Therapies' (OSTX) "Buy" Rating Reaffirmed at D. Boral CapitalJune 30, 2025 | marketbeat.comOS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor ...June 30, 2025 | finance.yahoo.comOS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma ConferenceJune 30, 2025 | businesswire.comOS Therapies Stock Surges 12.4% After Positive FDA Feedback on OST-HER2June 24, 2025 | msn.comOS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic OsteosarcomaJune 24, 2025 | businesswire.comOS Therapies Announces Warrant Exercise Inducement & Exchange OfferJune 23, 2025 | businesswire.comOS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic OsteosarcomaJune 10, 2025 | prnewswire.comOSTX OS Therapies IncorporatedJune 1, 2025 | seekingalpha.comBuy Rating for OS Therapies: Promising Developments and Strategic Positioning in Cancer ImmunotherapyMay 21, 2025 | tipranks.comOS Therapies Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 16, 2025 | businesswire.comOS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine OsteosarcomaMay 15, 2025 | finance.yahoo.comOS Therapies Inc (NYSE:OSTX) Major Shareholder Shalom Auerbach Sells 82,000 SharesMay 10, 2025 | insidertrades.comOS Therapies Inc sees $163,918 in stock sales by major shareholderMay 9, 2025 | investing.comOS Therapies secures patent for cancer immunotherapy techMay 8, 2025 | investing.comEmmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer TherapiesMay 2, 2025 | businesswire.comOS Therapies granted FDA meeting for OST-HER2April 22, 2025 | markets.businessinsider.comOS Therapies FDA Meeting Request GrantedApril 22, 2025 | businesswire.comOS Therapies Inc (NYSE:OSTX) Major Shareholder Sells $67,516.20 in StockApril 12, 2025 | insidertrades.comOS Therapies Announces Positive Data From The Study Of OST-HER2 In Osteosarcoma In DogsApril 12, 2025 | nasdaq.comOS Therapies Inc: Shalom Auerbach sells $81,566 in common stockApril 11, 2025 | investing.comOS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in HumansApril 10, 2025 | businesswire.comOS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala PharmaceuticalsApril 9, 2025 | businesswire.comLake Street Initiates Coverage of OS Therapies (OSTX) with Buy RecommendationApril 3, 2025 | msn.comOS Therapies Inc Reports 2024 Net Loss Per Share of $0. ...April 1, 2025 | gurufocus.comOS Therapies Reports Full Year 2024 Financial Results and Provides Business UpdateMarch 31, 2025 | businesswire.comOS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human OsteosarcomaMarch 31, 2025 | businesswire.comOS Therapies’ OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer PioneersMarch 25, 2025 | finance.yahoo.comOS Therapies' OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer PioneersMarch 25, 2025 | businesswire.comOS Therapies (OSTX): Among the Penny Stocks With Huge Upside Potential According to AnalystsMarch 23, 2025 | insidermonkey.com Get OS Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OSTX Media Mentions By Week OSTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OSTX News Sentiment▼0.150.93▲Average Medical News Sentiment OSTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OSTX Articles This Week▼12▲OSTX Articles Average Week Get the Latest News and Ratings for OSTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for OS Therapies and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Larimar Therapeutics News Today Ocugen News Today Monte Rosa Therapeutics News Today DiaMedica Therapeutics News Today scPharmaceuticals News Today Contineum Therapeutics News Today 4D Molecular Therapeutics News Today Capricor Therapeutics News Today Foghorn Therapeutics News Today Lifecore Biomedical News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:OSTX) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OS Therapies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share OS Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OSTX Stock Alerts